A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy of the biweekly pemetrexed/gemcitabine
regimen when given to patients with metastatic breast cancer. Each agent has well
demonstrated antitumor activity in patients with locally advanced or metastatic breast
cancer. In addition, in the phase I combination trial of the two agents, a durable tumor
response was seen in one out of three heavily pretreated breast cancer patients (Adjei et al.
2000). Therefore, it is reasonable to expect that the combination of pemetrexed and
gemcitabine administered may be associated with considerably more anti-tumor activity than
either agent alone. If such activity is seen in this study, randomized studies comparing this
combination with other active agents or combinations of active agents will be considered.